$0.60
-0.01(-1.55%)
Mkt Cap $8M
$0.36
$1.61
52-Week Range
At a Glance
AI-generatedImpact BioMedical Inc.
Revenue breakdown: Biotech Retail Sales (100%).
8-K
Impact BioMedical Inc. entered into Amendment No. 1 dated February 27, 2026, to its Merger and Share Exchange Agreement originally dated June 21, 2025, with Dr Ashleys Limited, Dr Ashleys Bio Labs Limited, and others. The amendment provides for issuance of 22,000 Compensation Shares to CEO Frank D. Heuszel and up to 128,000 DSS Shares to DSS, Inc., deducted from Company Share Consideration of 169,560,000 PubCo ordinary shares (94.20%), extends termination End Date to July 1, 2026, and adds loan co-signing provisions.$8M
Market Cap
—
Revenue
—
Net Income
Employees2
Fundamentals
How The Business Makes Money
Revenue by Segment
Biotech Retail Sales100%($32.0K)
Activity
Company Profile
CIK0001834105
ISINUS45259L2051
CUSIP45259L205
Phone585-325-3610
Address1400 Broadfield Blvd., Houston, TX, 77084, US
SEC EDGAR